The Belgian drugmaker is buying the two-year-old San Diego biotech for $2 billion, its second TCE bet in as many months. Thesis: B-cell killers engineered for cancer could redefine how autoimmune diseases are treated.
Candid Therapeutics is two years old. It has no approved medication. Its flagship program has been tested in nearly 100 patients in multiple early-stage trials. on sunday UCBThe Brussels-listed pharmaceutical company agreed to buy it for $2.2 billion.
This kind of price for this kind of biotech needs an explanation, and in 2026 the explanation has a name: Connects T-cells in autoimmune disease.
Under the deal announced May 3, UCB will pay $2 billion in cash, with up to $200 million in additional milestone payments depending on development and regulatory progress.
💜 of EU technology
The latest rumblings from the EU tech scene, a story from our wise founder Boris and some questionable AI art. Free in your inbox every week. Register now!
The contract is expected to be closed at the end of the second quarter or the beginning of the third quarter, subject to antitrust clearance. UCB has confirmed financial guidance for 2026, indicating it intends to absorb the transaction without lowering expectations.
This is the second time in a few months that the Belgian company has resorted to the same therapeutic mechanism. In an earlier transaction, UCB licensed the CD19/CD3 bispecific ATG-201 from China-based Antengene in a deal worth up to $1.1 billion. Candida uptake builds on this and adds a different B cell target.
What does Candid really have?
Candida’s lead active ingredient is cizutamig, a bispecific antibody designed to bridge the two cells: it captures the T-cell via CD3 on one end and the plasma cell via BCMA, a B-cell maturation antigen, on the other, and instructs the T-cell to destroy the plasma cell.
The mechanism was developed for multiple myeloma, where killing rogue plasma cells is the whole point of treatment. The 2026 thesis is that the same engine could be used to deplete the autoreactive B-cells and plasma cells that drive autoimmune diseases like lupus, myasthenia gravis, and a long list of lesser-known conditions in which the immune system attacks its own tissues.
According to UCB, cizutamig has now been clinically evaluated in more than 100 patients in multiple myeloma and autoimmune indications combined, and is currently in Phase 1 studies in more than a dozen autoimmune diseases.
In its statement, UCB describes it as the potential best BCMA T-cell for autoimmune diseases, which is both ambitious and conventional language for such press releases.
The reason buyers are willing to write a nine-figure check on Phase 1 data is because the early autoimmune signals from this drug class are generally really surprising. Patients with severe disease have shown sustained remissions after a course of B-cell-depleting therapy, including in settings where decades of small-molecule and biologic therapy have provided only partial control. None of this is certain yet.
Final phase data, larger cohorts, and longer follow-up will be required. But the trend has been consistent enough that boards of pharmacy have begun to consider the modality as a business.
Candid was founded in 2024 in San Diego, with backing from Two River Group and Vida Ventures and $370 million in seed funding. Its chairman, CEO and president is Dr. Ken Song, who previously led RayzeBio to its $4.1 billion acquisition by Bristol Myers Squibb in late 2023. Building, scaling up and selling clinical-stage oncology and immunology biotechs, in other words, is his job.
This date is part of what UCB pays. Buyers in this segment of the market are increasingly willing to provide quality control along with quality of molecules, especially when the commercial promise of a molecule depends on disciplined test design across a large number of small indicators.
The valuation gap between the initial $370 million in seed funding in mid-2024 and the $2 billion seed funding that UCB paid in cash less than two years later is a fair indication of what investors think it and its team are building.
It’s also a sharp turn. In March, Candid announced a reverse merger with Rallybio, a publicly listed but smaller rare disease company, intending to take Candid public through a backdoor listing. This operation has apparently now been superseded. UCB’s offer was probably better.
UCB’s acquisition fits a pattern that is hard to miss. Over the past nine months, every major pharmaceutical company in the field of immunology has either acquired, licensed, or partnered with T-cells targeting autoimmune diseases.
Gilead acquired Ouro Medicines earlier this year for $2.18 billion, picking up another BCMAxCD3 participant, gamgertamig. Sanofi has granted a trispecific license from Kali Therapeutics in a deal worth up to $1.2 billion. GSK paid $300 million to license CMG1A46 candidate from Chimagen for lupus. Prolium Bioscience raised $50 million in March to develop a CD20xCD3 engager. The list grows almost every week.
Two facts explain the rush. First, science finally seems to be able to generalize; What works in oncology to remove malignant B-cells works in autoimmune diseases to remove autoreactive ones, and the first human data are better than predicted in the usual pharmacology textbook.
The second is that immunology is by some distance the largest pharmaceutical market in the world, after oncology. Drugs like AbbVie’s Humira, ahead of the erosion of biosimilars, and Sanofi’s Dupixent are reminders that successful autoimmune therapies generate revenue on a scale that only a few categories desire.
If TCEs work in this setting, the reward is correspondingly large. If they don’t, a few of these deals will look expensive in retrospect.
Where AI talk doesn’t quite fit
It is necessary to note what does not lead to the contract. Despite the growing focus on AI-discovered drugs, Google DeepMind spinoff Isomorphic Labs, which entered trials this year ByteDance’s New Labs introduces its first AI-designed therapy and Anthropic pays $400 million for 10-person biotech startup cizutamig itself is a conventionally developed biologic to make protein-based drugs.
It was discovered through licensing relationships and standard antibody engineering rather than through generative protein models. The molecules driving today’s influx of autoimmune deals are almost invariably products of the chemistry of a decade ago.
Artificial intelligence has promised to accelerate drug discovery has so far produced more announcements than endorsements.
A bona fide bargain, in this sense, is a reminder that pharma’s greatest near-term value creation occurs in molecules that are in the pipeline before the AI ​​hype cycle begins. Subsequent acquisitions in two or three years may include candidates discovered by artificial intelligence. There is no need for that.
What UCB has now and what it has to prove
The strategic logic for UCB is clear. The company is a mid-sized pharmaceutical company with a long-standing immunology franchise and recent experience in opening new therapeutic areas through targeted M&A.
Combining Antengene’s CD19xCD3 candidate with Candid’s BCMAxCD3 lead asset gives it mechanisms to deplete two complement B-cells in a market that increasingly appears to prize platform breadth over single-molecule excellence.
What UCB has to prove is execution. Phase 1 data in autoimmune disease are encouraging but subtle. The intensity of competition is unusually high, with at least half a dozen major pharmaceutical companies pursuing similar mechanisms for overlapping indications. Pricing pressure from both regulators and payers will hit any successful TCE as it nears approval. And production of bispecific antibodies at scale is non-trivial. None of these are fatal. It’s all real.
When the deal closes this summer, the broader market may have upped or down its enthusiasm for the modality. UCB chose to act before this amendment.
Whether this is timely or costly will be seen in Phase 2 studies over the next 18 months. The two-year-old company, which began as a bet on autoimmune disease by a seasoned operator, has been valued at $2.2 billion in cash by a pharmaceutical company that is now convinced the bet was right.
